These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30287281)

  • 21. [Alternative scaffold proteins].
    Petrovskaia LE; Shingarova LN; Dolgikh DA; Kirpichnikov MP
    Bioorg Khim; 2011; 37(5):581-91. PubMed ID: 22332353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies.
    Dimasi N; Fleming R; Wu H; Gao C
    Methods; 2019 Feb; 154():77-86. PubMed ID: 30102989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
    Patke S; Li J; Wang P; Slaga D; Johnston J; Bhakta S; Panowski S; Sun LL; Junttila T; Scheer JM; Ellerman DA
    MAbs; 2017 Apr; 9(3):430-437. PubMed ID: 28125314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering high affinity antigen-binders: Beyond conventional antibodies.
    Pandey RK; Mehrotra S
    Adv Protein Chem Struct Biol; 2024; 140():37-57. PubMed ID: 38762275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Affibody molecules as engineered protein drugs.
    Frejd FY; Kim KT
    Exp Mol Med; 2017 Mar; 49(3):e306. PubMed ID: 28336959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
    Albrecht H; Denardo GL; Denardo SJ
    J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative non-antibody scaffolds for molecular recognition.
    Skerra A
    Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.
    Van Blarcom T; Lindquist K; Melton Z; Cheung WL; Wagstrom C; McDonough D; Valle Oseguera C; Ding S; Rossi A; Potluri S; Sundar P; Pitts S; Sirota M; Galindo Casas M; Yan Y; Jones J; Roe-Zurz Z; Srivatsa Srinivasan S; Zhai W; Pons J; Rajpal A; Chaparro-Riggers J
    MAbs; 2018; 10(2):256-268. PubMed ID: 29227213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rigidly connected multispecific artificial binders with adjustable geometries.
    Wu Y; Batyuk A; Honegger A; Brandl F; Mittl PRE; Plückthun A
    Sci Rep; 2017 Sep; 7(1):11217. PubMed ID: 28894181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage.
    Eggel A; Baumann MJ; Amstutz P; Stadler BM; Vogel M
    J Mol Biol; 2009 Oct; 393(3):598-607. PubMed ID: 19683003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
    Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
    Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered affinity proteins--generation and applications.
    Grönwall C; Ståhl S
    J Biotechnol; 2009 Mar; 140(3-4):254-69. PubMed ID: 19428722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Developments Toward Antibody Engineering and Affinity Maturation.
    Rathore AS; Sarker A; Gupta RD
    Protein Pept Lett; 2018; 25(10):886-896. PubMed ID: 30255742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Building blocks for bispecific and trispecific antibodies.
    Wu X; Demarest SJ
    Methods; 2019 Feb; 154():3-9. PubMed ID: 30172007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering novel binding proteins from nonimmunoglobulin domains.
    Binz HK; Amstutz P; Plückthun A
    Nat Biotechnol; 2005 Oct; 23(10):1257-68. PubMed ID: 16211069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
    Igawa T
    Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
    Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA
    Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.